(Received for publication January 26, 2000) Twelve of the fourteen isolated components of the luminacin family were assayed for activity to inhibit capillary tube formation in vitro. Seven of them showed potent activity with IC50 values of less than 0.1 /ig/ml in a rat aorta matrix culture model. Luminacin D, the strongest inhibitor, inhibited both endothelial cell proliferation and capillary tube formation. Angiogenesis consists of capillary formation from preexisting vessels and is stringently controlled under normal circumstances in the adultl\ However, angiogenesis can be activated in response to tissue injury or inflammation, which are closely related to pathological situations such as rheumatoid arthritis and diabetic retinopathy2). Solid tumors also stimulate angiogenesis, and the concept that the tumor growth depends on angiogenesis is well established3Ŝ everal angiogenesis inhibitors are currently undergoing clinical trials as antitumor agents. 
Rat Aorta Matrix Culture Assay
Rat aorta matrix gels were prepared by the method described previously8). Briefly, thoracic aortas were obtained from 8-to 12-week-old male Sprague-Dawley rats. The flbroadipose tissue around the aorta was carefully removed and rinsed with Hank's solution. The aortas were cut into small fragments (2 X2 mm) and transferred to wells of a 24-well culture plate containing collagen gel (0.5 ml). After collagen gelation, MCDB131 medium (0.5 ml) was added on top of the gel in the wells. The mediumwas changed to extract-or luminacin-containing mediumon day 2 and on day 5. At 7days after the beginning of the experiment, (day 8), microvessels were counted under a light microscope. For assay of tube disruption, 1ml of medium containing luminacin was added to the gels.
Testing was conducted using four cultures per dose and results were confirmed by repeated experiments.
Cell Growth Assay
Cells were seeded on a 96-well culture plate at 1X103 cells/well for HUVECand 2X 103 cells/well for other cells, followed by addition of luminacin on the next day. At 3 days after addition of luminacin, the ratios of surviving cells were measured by means of the MTTassay14). All experiments were done at least in duplicate. 
Results
In the RATFmodel, new microvessels originate from the ends of aortic fragments within type I collagen gel under a serum-free medium. Migrating cells appear after 3 to 5 days, followed by microvascular sprouts, and vascular growth continues for 1 to 2weeks. Luminacin D remarkably decreased the number of capillary tubes in a dose-dependent manner in 7 days (Fig. 1) . The inhibitory activity was very strong and the IC50 value was 0.017 jUg/ml. Nevertheless, the number of migrating cells was hardly decreased and the cells were located around the aortic fragment, with cell-cell contact. Twelve components of the luminacin inhibitor complex were investigated, and the results are shown in Table 1 . Twocomponents, E3 and G2, were not available in sufficient amountto examine the activity. The potency was classified into high, moderate and low categories.
The highly active group consisted of luminacins Cl5 C2, D, El5 E2, F and G^Luminacin H was moderately active. Luminacins A1? A2, B{ and B2 were in the low activity group, showing no inhibition at less than 1 /ig/ml. These groups correspond with the structural classification according to the C-l substituent of benzene chromophore (see our previous report1!)). Since luminacin derivatives showed anti-angiogenesis activity in the RATF model, the growth-inhibitory activity toward endothelial cells was also investigated (Table 1 ). All the luminacins inhibited the growth of HUVEC, though the activities of the four componentsin the low activity group were as weak as they were in the RATFmodel. However, in the high activity group, the potencies of endothelial cell growth inhibition did not coincide with the activities in the RATF model. Luminacin D was less active (IC50 0.18^g/ml) and E2 was the most potent (IC50 0.06 jUg/ml), suggesting that the anti-angiogenesis activity in the RATFmodel resulted from both endothelial cell growth inhibition and another mechanismof action. Rat aortic fragments were cultured with luminacin D at the indicated concentrations in collagen gel for 7 days. The numberof capillary tubes was counted periodically under a microscope. Data are expressed as means(n=4). In order to clarify the presumed second mode of action of luminacin D, we investigated the activity in a collagen gel sandwich model (TF) which forms a tube-like network of endothelial cells in 4 days when HUVEC cultured on Type I collagen gel are overlaid with a second collagen gel (Fig. 2-A, B ). In this model, proliferation is completely suppressed and the relevant event is capillary tube formation, including cellular reorganization or adhesion/ dysadhesion. Luminacin D clearly inhibited the formation of tube-like network in a dose-dependent manner, as shown in Fig. 2 . It was active at the concentration of 0.1 /ig/ml of luminacin D (Fig. 2-D) , and morphological change was dramatically observed at more than 1 /ig/ml ( Fig. 2-E, F) . The observations were consistent with those in the RATF model. Cells did not begin to form a network, and the cellcell contact remained tight. The cell number did not decrease even at the concentration of 3 jiglvcA in 4 days ( Fig. 2-F angiogenesis inhibitors derived from microbial metabolites, including fumagillin15), eponemycin16), radicicol17) and rhizoxin18).
It has been reported that TNP-470, a synthetic derivative of fumagillin, selectively inhibits endothelial cell proliferation through inhibiting methionine aminopeptidase19), while eponemycin inhibits proliferation and cell migration of endothelial cells, radicicol inhibits some protein kinase activities20) and rhizoxin exhibits anti-tubulin activity21). Thus, although an epoxide structure may be important for anti-angiogenesis activity, it does not seem to determine the target molecule. The results also suggest that the carbonyl structure in the benzene moiety is important for high activity. Further work is needed to establish the structure-activity relationship of luminacins in detail. The RATFmodel permits us to observe the course of the angiogenesis process, i.e., cell migration, proliferation and tube formation. The modeof inhibitory action of luminacin was different from those of other natural inhibitors tested, also did not impair cell migration (data not shown). On the other hand, luminacin inhibited cell scattering and the cells formed a sheet-like structure around aortic fragments. These results strongly suggest that luminacin has an unique activity. This mode of action could be dramatically observed in the TF model, in which interaction of type I collagen fibrils with the apical cell membrane induces tube formation. Signals including angiogenic factors are transmitted into the cytoplasm and nuclei, leading to cell rearrangement27).
It may be that luminacin D blocks one of the signaling pathways, because the cell morphology in the presence of a high concentration of luminacin D did not change to form a network structure after the second collagen gel was overlaid (Fig. 2) . In other words, luminacin may modulate cell-cell and/or cell-ECM adhesion. Although little is knownabout the molecular mechanism of capillary tube formation, adhesion molecules such as cadherin 528), CD 3129) and integrin a230) seem to play roles. Antibody experiments have demonstrated that inter-and intracellular interactions via these adhesion molecules are necessary for tube formation. Furthermore, the expression levels of these molecules change in the process of tube formation. Molecules closely related or identical to luminacin C{ and C2 are known as mentioned in our previous report.
However, this is the first report of anti-angiogenic activity of such compounds, and the other twelve components of luminacin are structurally novel. The reported compounds showed activities of immunosuppression31) and low density lipoprotein (LDL) uptake enhancement32). The relationship, if any, of these activities to the angiogenic activity remains to be established. Weare currently planning to examine further the antiangiogenic activity of luminacins in animal models, including solid tumor models. 
